TNFSF13
ENSG00000161955
Target class
Secreted protein
Chromosome
17
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- TNFSF13
- Gene name
- TNF superfamily member 13
- Gene symbol
- TNFSF13
- Protein name
- Tumor necrosis factor ligand superfamily member 13 (A proliferation-inducing ligand) (APRIL) (TNF- and APOL-related leukocyte expressed ligand 2) (TALL-2) (TNF-related death ligand 1) (TRDL-1) (CD antigen CD256)
- APRIL
- CD256
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 96.18
- Tissue specificity (Gini)
- 0.307
- Tissue specificity (tau)
- 0.68
- KEGG gene identifiers
- hsa:8741
- Protein interaction confidence
- 0.8762
- Protein interaction partners
- 10
- R-HSA-450520
- R-HSA-5669034
- End position
- 7561608
- Start position
- 7558292
- Chromosome
- 17
- Strand
- Forward
- Secreted .
Publication evidence
- PubMed 11571266
- Tissue specificity (tau)
- 0.680132
- Expression inequality (Gini)
- 0.307294
Expression in transcripts per million
- Lung
- 96.18
- Minor Salivary Gland
- 85.13
- Kidney - Medulla
- 68.45
- Nerve - Tibial
- 60.09
- Artery - Aorta
- 55.05
Expression in transcripts per million
- Lung96.18
- Minor Salivary Gland85.13
- Kidney - Medulla68.45
- Nerve - Tibial60.09
- Artery - Aorta55.05
- Whole Blood50.42
- Thyroid49.78
- Spleen49.56
- Ovary45.72
- Fallopian Tube45
- Cervix - Endocervix44.89
- Kidney - Cortex42.25
- Stomach41.62
- Artery - Coronary40.7
- Colon - Transverse40.38
- Brain - Caudate (basal ganglia)39.67
- Adipose - Visceral (Omentum)39.3
- Prostate38.85
- Brain - Nucleus accumbens (basal ganglia)37.38
- Cervix - Ectocervix35.23
- Adrenal Gland34.29
- Brain - Putamen (basal ganglia)32.94
- Small Intestine - Terminal Ileum31.97
- Brain - Cortex31.58
- Breast - Mammary Tissue31.11
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0008284
- GO:0048298
- GO:0005576
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0070062
- GO:0005102
- GO:0005515
Related records
Trials (26)
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
- Atacicept Demonstrating Dose RESponSe
- Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
- Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)
- Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
- Atacicept in Multiple Glomerular Diseases
- Atacicept in Multiple Sclerosis Extension Study, Phase II
- Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
- Atacicept in Subjects With IgA Nephropathy
- Atacicept in Subjects With Optic Neuritis
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
- CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
- Efficacy and Safety of Atacicept in IgA Nephropathy
- Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
- First in Human Study to Assess Safety of VIS649 in Healthy Subjects
- Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)
- Monthly Dosing of Atacicept in IgAN
Drugs (2)
- Atacicept Tumor necrosis factor ligand superfamily member 13 inhibitor
- Sibeprenlimab Tumor necrosis factor ligand superfamily member 13 inhibitor